Physician profile
Jill S Nelson
NPI 1164531158
$3,270.36
in general payments reported to CMS, 2019-2025
14 companies · $91.81 in 2025
The $91.81 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,756 · 2021: $48.63 · 2022: $93.87 · 2023: $63.17 · 2024: $216 · 2025: $91.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,772.94 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $119.54 | 2022-2025 | Sotyktu |
| Abbvie INC. | $95.04 | 2021-2024 | |
| Amgen INC. | $53.48 | 2023-2025 | Otezla, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $37.44 | 2021-2023 | |
| Galderma Laboratories, L.P. | $33.33 | 2024-2025 | Aklief, Nemluvio |
| Janssen Biotech, INC. | $27.28 | 2019-2024 | Tremfya |
| Dermavant Sciences, INC. | $26.92 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $25.79 | 2024 | Dupixent |
| Organon LLC | $20.50 | 2025 | Vtama |
| Biofrontera INC. | $19.62 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.06 | 2022 | |
| Ucb, INC. | $15.11 | 2021 | |
| Mayne Pharma Commercial LLC | $5.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.